Specialty Pharmaceuticals - Nephrology & Iron Deficiency Therapies
Strategic Profile
Vifor Pharma operated as a specialty pharmaceutical company leveraging a joint venture with Fresenius Medical Care for nephrology products. The business focused on high-unmet-need therapeutic areas supported by in-licensing and strategic partnerships.
Cyborg Score Rationale
Company acquired by CSL Limited in August 2022 and now operates as a subsidiary. Independent public trading status ended at acquisition close.
Top Insights
Iron franchise (Ferinject/Injectafer) generated strong growth; patent exclusivity in US extended through July 2026 at time of last public disclosure.
Nephrology market estimated at over $25 billion by 2026 with aging population driving chronic kidney disease prevalence and treatment demand.
Company maintained strategic partnership with Fresenius Medical Care through joint venture (VFMCRP) for integrated nephrology platform and market access.
Recent Developments
(August 2022) Acquisition by CSL Limited completed for USD $179.25 per share (USD $11.7B equity value)
(December 2021) CSL Limited announced definitive agreement to acquire Vifor Pharma
(2021) Expanded into vascular calcification disorders through Sanifit and Inositec acquisitions
Open the full interactive Vifor Pharma Ltd report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.